The pathophysiology and management of primary pulmonary hypertension.
Primary pulmonary hypertension is a relatively rare disease with a poorly understood pathophysiology, limited therapeutic options, and a dismal prognosis. The advantages and disadvantages of different pharmacologic approaches for this condition are discussed in this article.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D011651:Pulmonary Artery / Q000473:pathology; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents